FDA Approves Ear Tube Delivery System That Does Not Require General Anesthesia
The FDA has approved the Tubes Under Local Anesthesia (Tula) System (Tusker Medical) for the treatment of recurrent otitis media in patients ≥6 months of age.
The FDA has approved the Tubes Under Local Anesthesia (Tula) System (Tusker Medical) for the treatment of recurrent otitis media in patients ≥6 months of age.
Perioperative opioid fills linked to risk of return visit for constipation but not pain, dehydration or hemorrhage.
Early identification and intervention could reduce risk for these poor health outcomes.
The FDA has approved SYNCHRONY and SYNCHRONY 2 (MED-EL) cochlear implant systems for single-sided deafness and asymmetric hearing loss.
Associations particularly pronounced for Rx opioid use disorders in those aged 18 to 34 with hearing loss.
Reduced morbidity associated with a minimum hospital volume threshold of 6 cases/year.
Nasal decongestants can be used for short periods for adults; their safety is unclear for children.
Bose Hearing Aid is user-fitted device for people 18 and older with mild-to-moderate hearing loss.
A short course of oral steroids was not found to significantly improve otitis media with effusion in children.
Cleft lip and palate is defined as congenital malformation of the upper lip and/or oral cavity disrupting normal facial structure and oromotor function.